As FogPharma’s Chief Data Officer, Dr. Lihua Yu is responsible for the development and implementation of data science strategy across all R&D functions and research programs, as well as establishing informatics and machine learning systems to power the design-make-test-predict cycle of our proprietary Helicon™ platform.
Dr. Yu brings over 20 years of experience and leadership in data science across computational biology, cancer genomics, research informatics, clinical genomics, real world data and evidence.
Prior to joining FogPharma, Dr. Yu was the President and Chief Data Science Officer at H3 Biomedicine Inc. and served in multiple roles during her near a decade tenure. At H3, she held overall responsibilities for the company’s R&D. As their Chief Data Science Officer, Dr. Yu was responsible for driving the expanded use of data and technology and leading the creation of a data science/cancer genomics/information-sharing engine supporting all phases of drug discovery and early clinical development. She led H3 during its transition from a drug discovery company to an early phase drug development company. Prior to H3, she was the Cancer Bioinformatics Leader at AstraZeneca and held roles of increasing responsibility from 2000-2011.
Dr. Yu earned her Ph.D. in Biomedical Engineering from Boston University working under Dr. Temple Smith, and her M.S. and B.S. in Biomedical Engineering from Tsinghua University, Beijing, China.